Tumor, Solid Clinical Trial
Official title:
Evaluating the Potential Usefulness of 68Ga-FAP-2286 PET/CT in Patients With Various Types of Cancer and Compared With 18F-FDG PET/CT
To evaluate the potential usefulness of 68Ga-FAP-2286 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and compared with 18F-FDG PET/CT.
Subjects with various types of cancer underwent contemporaneous 68Ga-FAP-2286 and 18F-FDG PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of 18F-FDG and 68Ga-FAP-2286 PET/CT were recorded by visual interpretation. The sensitivity, specificity, and accuracy of 68Ga-FAP-2286, 18F-FDG PET/CT were calculated and compared to evaluate the diagnostic accuracy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05637034 -
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
|
N/A | |
| Terminated |
NCT04095091 -
Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
|
||
| Recruiting |
NCT05378425 -
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT04723810 -
TumorGlow Intraoperative Molecular Imaging (IMI)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
| Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
| Terminated |
NCT01358331 -
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
|
Phase 1 | |
| Recruiting |
NCT06175221 -
Autologous TLPO Vaccine Basket
|
Phase 2 | |
| Recruiting |
NCT05661461 -
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
|
Phase 1 | |
| Active, not recruiting |
NCT04196530 -
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
|
Phase 1 | |
| Not yet recruiting |
NCT03731390 -
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06193902 -
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04528836 -
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05221320 -
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
|
Phase 2 |